PORTO, Portugal–(BUSINESS WIRE)–FairJourney Bio (FJBio), a global leader in antibody discovery and development, announced today that its Chief Executive OfficerPORTO, Portugal–(BUSINESS WIRE)–FairJourney Bio (FJBio), a global leader in antibody discovery and development, announced today that its Chief Executive Officer

FairJourney Bio to present at J.P. Morgan 2026 Healthcare Conference

PORTO, Portugal–(BUSINESS WIRE)–FairJourney Bio (FJBio), a global leader in antibody discovery and development, announced today that its Chief Executive Officer, Dr. Werner Lanthaler, will present at the J.P. Morgan 2026 Healthcare Conference, taking place from January 12 – 15, 2026 in San Francisco, CA.

With more than a decade of expertise, FJBio has supported over 250 clients across Pharma, Biotech and Academia and contributed to more than 19 antibodies advancing to clinical stage development or the market. During his presentation, Dr. Lanthaler will address FJBio’s strategic positioning as a highly efficient, integrated partner. He will showcase the Company’s antibody discovery and development solutions, with a focus on innovation, data-driven platforms and scalable collaboration models across the biopharmaceutical ecosystem.

Presenter

Role

Date

Time

Venue

Dr. Werner Lanthaler

CEO, FJBio

Jan 13

09:00–09:25 AM

“Golden Gate” at THE WESTIN, 32nd floor

In addition to the CEO presentation, members of FJBio’s Senior Management and Business Development teams will attend the conference for strategic discussions with representatives of global pharmaceutical companies, biotechnology innovators and other industry partners throughout the event.

Dr. Werner Lanthaler, Chief Executive Officer of FairJourney Bio, commented: “I look forward to presenting FairJourney Bio’s unique platform for partnered pipeline building at this year’s J.P. Morgan 2026 Healthcare Conference. This conference brings together a highly curated group of global healthcare leaders and innovators and I appreciate the opportunity to engage in meaningful dialogue around the future of efficient, data-enabled antibody discovery and development.”

Participation as a presenting company at this conference is highly selective and considered a significant distinction, reflecting FJBio’s growing global recognition and relevance within the international life sciences community. The conference provides an important platform for FJBio to strengthen existing relationships, explore new strategic partnerships and further position the Company as a trusted global partner across the full value chain.

Contacts

FairJourney Biologics
Hinnerk Rohwedder

Head of Marketing & Communications

hrohwedder@fjbio.com

Zyme Communications

Lily Jeffery
Email: lily.jeffery@zymecommunications.com
Tel: +44 (0)7891 477 378

Market Opportunity
BIO Protocol Logo
BIO Protocol Price(BIO)
$0.04277
$0.04277$0.04277
-0.94%
USD
BIO Protocol (BIO) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

WIF Price Prediction: Dogwifhat Targets $0.47 Breakout After Recent Whale Accumulation

WIF Price Prediction: Dogwifhat Targets $0.47 Breakout After Recent Whale Accumulation

The post WIF Price Prediction: Dogwifhat Targets $0.47 Breakout After Recent Whale Accumulation appeared on BitcoinEthereumNews.com. James Ding Jan 15, 2026
Share
BitcoinEthereumNews2026/01/16 06:53
Trading time: Tonight, the US GDP and the upcoming non-farm data will become the market focus. Institutions are bullish on BTC to $120,000 in the second quarter.

Trading time: Tonight, the US GDP and the upcoming non-farm data will become the market focus. Institutions are bullish on BTC to $120,000 in the second quarter.

Daily market key data review and trend analysis, produced by PANews.
Share
PANews2025/04/30 13:50
IP Hits $11.75, HYPE Climbs to $55, BlockDAG Surpasses Both with $407M Presale Surge!

IP Hits $11.75, HYPE Climbs to $55, BlockDAG Surpasses Both with $407M Presale Surge!

The post IP Hits $11.75, HYPE Climbs to $55, BlockDAG Surpasses Both with $407M Presale Surge! appeared on BitcoinEthereumNews.com. Crypto News 17 September 2025 | 18:00 Discover why BlockDAG’s upcoming Awakening Testnet launch makes it the best crypto to buy today as Story (IP) price jumps to $11.75 and Hyperliquid hits new highs. Recent crypto market numbers show strength but also some limits. The Story (IP) price jump has been sharp, fueled by big buybacks and speculation, yet critics point out that revenue still lags far behind its valuation. The Hyperliquid (HYPE) price looks solid around the mid-$50s after a new all-time high, but questions remain about sustainability once the hype around USDH proposals cools down. So the obvious question is: why chase coins that are either stretched thin or at risk of retracing when you could back a network that’s already proving itself on the ground? That’s where BlockDAG comes in. While other chains are stuck dealing with validator congestion or outages, BlockDAG’s upcoming Awakening Testnet will be stress-testing its EVM-compatible smart chain with real miners before listing. For anyone looking for the best crypto coin to buy, the choice between waiting on fixes or joining live progress feels like an easy one. BlockDAG: Smart Chain Running Before Launch Ethereum continues to wrestle with gas congestion, and Solana is still known for network freezes, yet BlockDAG is already showing a different picture. Its upcoming Awakening Testnet, set to launch on September 25, isn’t just a demo; it’s a live rollout where the chain’s base protocols are being stress-tested with miners connected globally. EVM compatibility is active, account abstraction is built in, and tools like updated vesting contracts and Stratum integration are already functional. Instead of waiting for fixes like other networks, BlockDAG is proving its infrastructure in real time. What makes this even more important is that the technology is operational before the coin even hits exchanges. That…
Share
BitcoinEthereumNews2025/09/18 00:32